biostudies-literatureUnknown31(9)Fasching PANovartis Pharmaceuticals Corporation (NPC)Novartis Pharmaceuticals Corporation<h4>Purpose</h4>The phase III NATALEE trial reported a statistically significant invasive disease-free survival benefit with ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus an NSAI alone in stage II/III hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer. In this study, we report health-related quality of life (HRQOL) data from NATALEE.<h4>Patients and methods</h4>Patients were randomized to receive ribociclib plus NSAI or NSAI alone. Patient-reported outcome scores [European Organisation for Research and Treatment of Cancer core quality of life questionnaire global health status and physical, social, and emotional functioning domains; the supplementary European Organisation for Research and Treatment of Cancer breast cancer-specific QOL questionnaire brClinical cancer research : an official journal of the American Association for Cancer Research1625-1635https://www.ebi.ac.uk/biostudies/studies/S-EPMC12010963biostudies-literatureHealth-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.PMC12010963Kukielka-Budny BRugo HSStroyakovskiy DChan AYardley DANowecki ZFasching PAFresco RChia SHuang CSLi ZSlamon DFerrusi IHurvitz SDanyliv AUntch MMartin MLoi SHortobagyi GAfenjar KfalseHealth-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.<h4>Purpose</h4>The phase III NATALEE trial reported a statistically significant invasive disease-free survival benefit with ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus an NSAI alone in stage II/III hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer. In this study, we report health-related quality of life (HRQOL) data from NATALEE.<h4>Patients and methods</h4>Patients were randomized to receive ribociclib plus NSAI or NSAI alone. Patient-reported outcome scores [European Organisation for Research and Treatment of Cancer core quality of life questionnaire global health status and physical, social, and emotional functioning domains; the supplementary European Organisation for Research and Treatment of Cancer breast cancer-specific QOL questionnaire br2025-01-01T00:00:00Z2025 May2026-06-03T04:52:30.012Z2025-07-08T03:12:25.078ZS-EPMC120109634001949310.1158/1078-0432.CCR-24-1724